Jubilant Ingrevia Ltd Q4 FY2023 Concall Summary

Key Takeaways

• A quarter defined by agrochemical destocking: Specialty Chemicals EBITDA fell sharply as agrochemical customers in the US and Europe slashed orders, creating a performance gap management calls the bottom.
• Niacinamide is turning, finally: After a brutal FY23 driven by avian flu and inventory liquidation, demand and price are both improving in the current quarter, with normalization expected by H2.
• New capacity is arriving at the right time: The 50,000-ton Acetic Anhydride expansion and two new GMP/non-GMP plants have been commissioned, setting up volume-led growth as end-market demand recovers.
• Management is confident FY24 EBITDA will be better than FY23, betting on H2 normalization in agrochemicals, a Niacinamide recovery, and operating leverage from new plants, even as Q1 remains weak.
• What to watch next quarter: Whether the promised H2 agrochemical demand recovery materializes on schedule, the pace of Niacinamide price improvement, and the ramp-up trajectory of the newly commissioned Acetic Anhydride and CDMO plants.

Specialty Chemicals: The Agrochemical Hole

• What broke in Q4: Demand from agrochemical customers collapsed, causing a significant drop in price realization for pyridine-derivative products like Paraquat and Diquat. Volumes were flat YoY for the segment, but revenue mix and pricing pressure dragged EBITDA down.
• Root cause is destocking, not China: Customers in the US and Europe are sitting on surplus finished agrochemical inventory because of lower end-demand in Brazil, the US, and Europe. Management explicitly stated this is not about Chinese competition recovering.
• Pricing pressure is real but contained: When global market conditions weaken, the company has to compete on price and margins go down. Raw material price fluctuations do not directly drive margin changes in Specialty Chemicals.
• The bottom call: Management stated, "I can fairly assume this is the bottom we are touching," and expects improvement from H2, based on customer feedback that destocking will run its course.
• The parallel that haunts this call: An analyst noted that both Nutrition headwinds and coal cost spikes were initially called short-term but persisted. Management did not directly address why this time is different, leaning on market readings and customer conversations.

Rajesh Srivastava: "I can fairly assume this is the bottom we are touching. We have to have improvement from here. May not be immediately, but as I said from H2 will be definitely coming back to the normal situation."

Nutrition: The Turnaround Begins

• FY23 was a double hit: Avian and swine flu in the US and EU slashed feed-grade Niacinamide demand, and then inventory liquidation across the supply chain compounded the pressure over the last 1.5 quarters. Revenue fell 28% for the full year.
• Both headwinds are now receding: The avian flu effect is gone, and inventory levels have normalized. Management sees clear improvement in both demand and pricing in the current quarter, with China having "really come out of material."
• Sequential volume improvement has started: Q4 volumes began picking up even while price remained under stress. Q1 FY24 has improved substantially, and Q2 is expected to be better still.
• The structural shift away from feed: A new cGMP-compliant facility for cosmetic-grade Niacinamide (3,000 TPA) has been approved, and a food-grade Vitamin B3 cGMP facility is in development. Both aim to reduce dependency on the volatile global feed market.
• Margin recovery target: Management hopes H2 can catch up to the previous ~20% EBITDA margin level for the Nutrition business.

Rajesh Srivastava: "Niacinamide, we can clearly see the improvement both in demand as well as pricing. And China has really come out of material. So obviously, situations are improving."

Chemical Intermediates: Steady, With New Capacity Coming Online

• Q4 showed volume strength: Revenue was lower YoY because Acetic Acid prices fell, dragging down price realization for Acetic Anhydride and Ethyl Acetate. But EBITDA was higher YoY due to higher volumes.
• Acetic Anhydride market is stable: Global demand continues to grow across several end-use segments, and new customers have been brought in, mainly in Europe, ensuring good utilization of the newly added 50,000-ton capacity.
• The ramp-up plan: The new Acetic Anhydride capacity has been commissioned, and the first quarter of sales from it will be the current quarter. Management plans to fully utilize it over the next 1.5 to 2 years, with quarter-on-quarter volume improvement.
• Base EBITDA should hold or improve: Unless severe market headwinds appear, Chemical Intermediates EBITDA should stay at similar levels or better because volumes will improve. Margin percentages may vary with Acetic Acid prices, but this is not a structural issue.
• Diketene derivatives utilization is also expected to continue improving in coming quarters.

New Plants & Capex: Capacity for the Recovery

• Three major commissions completed: A cGMP plant in Bharuch for global pharma CDMO clients, a non-GMP multipurpose plant in Gajraula for complex chemistries and pyridine derivatives, and the 50,000-ton Acetic Anhydride expansion.
• The GMP upgrade trade-off: Management took a conscious decision to upgrade the capacity of the new GMP facility during construction, which delayed the plant but will benefit in the longer term.
• Utilization ramp-up expected by H2: Both the cGMP and non-cGMP plants are expected to reach ~85% utilization (described as "100% utilized") from H2 of this year. CDMO revenue will normalize in H2 as the plant picks up capacity.
• Capex guidance is unchanged: The capex slide was removed from the presentation for cleanliness, not because of any change in plans. Revenue guidance from capex also remains unchanged, and management calls it realistic, not hypothetical.
• Food-grade acetic acid is progressing slowly: the GMP plant is being audited by customers, volumes are picking up gradually, and the facility is well placed for the customer segment.

Rajesh Srivastava: "In view of this during construction of our new GMP facility we have taken a conscious decision to upgrade the capacity, which though have delayed our GMP plant, however, will benefit us in longer term."

Energy Costs & Margin Levers

• Energy cost pressure has largely abated: Coal prices have come down, contracted coal volumes have started coming in, and operational efficiencies in generation and consumption have improved. Q4 energy costs were close to normal after very high costs in Q1-Q3.
• Gajraula power costs will fall further: Grid connectivity will reduce power costs at the Gajraula site, starting by end of Q2. Renewable energy sourcing from solar and wind is also in progress, with benefits starting next year onward, perhaps in 1.5 years.
• Sequential EBITDA degrowth of ~INR50 crore from Q3 to Q4 was not only from Specialty Chemicals: Nutraceuticals also saw a significant EBITDA drop, which is now improving.
• FY24 EBITDA confidence: Management is confident that FY24 EBITDA will be better than FY23, driven by H2 normalization in agrochemicals, Niacinamide recovery, and new plant operating leverage, even though Q1 remains weak.

Strategy & Portfolio Shifts

• Pyridine value-addition is the core logic: 40% of pyridine is consumed captively, and the objective is to add value over the next 3-4 steps rather than selling pyridine as a commodity. Every year, 4-5 new pyridine derivatives are launched.
• Nutrition is being derisked from feed: The cosmetic-grade and food-grade Niacinamide initiatives are explicitly designed to reduce high dependency on the global feed market and provide consistency to the Nutrition business.
• Ethyl Acetate and Specialty Ethanol will continue to be rationalized, with sales directed only to niche customers to optimize margins.
• Pharma vs. agro mix in Chemical Intermediates: Market share in paracetamol and ibuprofen remains strong and continues to grow. Other end-uses like agrochemical are growing faster, but pharma is not declining: volumes grow where the market grows.
• Management change was a non-event, per management: Mr. Anil Khubchandani left for another opportunity. Business unit heads are in place, a new leadership head has been appointed, and the succession pipeline is described as strong.

Shyam Bhartia: "Our objective is to add value to pyridine in next 3 or 4 steps and then meet the requirement rather than selling pyridine."

Guidance & Commitments

Key Metrics